PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PDL BioPharma Announces Fourth Quarter and Full Year 2013 Financial Results
PDL BioPharma to Announce Fourth Quarter and Full Year 2013 Financial Results on March 3, 2014
PDL BioPharma to Present at Upcoming Investor Conferences
PDL BioPharma and Paradigm Spine Complete a $75 Million Financing Transaction